BUSINESS
A fabulous budget for inclusive growth, focus on MSMEs heartening, says HUL's Sanjiv Mehta
FICCI president Subhrakant Panda, too, hails Budget 2023 for its focus on MSMEs, says it will lead to sustainable and resilient growth
BUSINESS
Budget 2023: ICICI Pru CIO S Naren sees a growth focused budget
He said that the government did what was possible and it’s a growth-oriented budget with very limited scope to give tax concessions at this point.
BUSINESS
Budget gave us all that we asked for and more, says Tata Steel MD Narendran
Narendran mentioned that the focus on railways was very crucial as it is often considered that the railways could be a big bottleneck for growth
BUSINESS
Budget 2023 balances growth with fiscal prudence, says CII president
Budget 2023: CII president Sanjiv Bajaj said that several recommendations made by the Confederation of Indian Industry found a place in this year’s Budget.
BUSINESS
UPL Q3 results: Net profit rises 16% YoY to Rs 1,087 crore
UPL Q3 results: The company reported a 21 percent YoY rise in consolidated revenue at Rs 13,679 crore.
BUSINESS
Sun Pharma Q3 net profit rises 5% to Rs 2,166 crore
The company also reported a 14 percent increase in consolidated revenue at Rs 11,241 crore as against Rs 9,863 crore in the year-ago period.
BUSINESS
Q3 Preview | UPL to see strong growth in Q3 earnings, driven by North America, Latin America markets
Europe growth to be muted amid tough market conditions.
BUSINESS
Sun Pharma profit may decline 10% in Q3 on poor operating performance
Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth.
BUSINESS
Dr Reddy’s reports 77% growth in Q3 consolidated profit
Dr Reddy's Q3 result: The drugmaker reported a 27% YoY increase in consolidated revenues at Rs 6,770 crore for the reported quarter.
BUSINESS
Cipla Q3 Result | Profit rises 10% YoY to Rs 801 crore, revenue up 6%
Revenues were aided by strong growth in US business supported by sustained traction in Indian business.
BUSINESS
Zomato sees steepest intraday fall in one year as it rebrands ‘Instant’
The stock fell 14 percent intraday on January 25, 2023, which is the steepest fall since January 24, 2022 when it saw a 19 percent drop
BUSINESS
Cipla Q3 preview | Consolidated net profit likely to rise 22% YoY
Cipla’s generic version of Revlimid may reinforce sales in the US and improve the EBITDA margin on a yearly basis
BUSINESS
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
Revlimid sale contribution to US revenue likely to fall as it normalises, making for a muted December Quarter
BUSINESS
Pharma Q3 Preview | Muted performance likely amid sluggish US sales, higher costs
Experts expect 8-11 percent YoY sales growth in Q3FY23. On the operating front they foresee growth of 4-10 percent YoY in EBITDA
BUSINESS
Sun Pharma to get growth boost with addition of Deuroxolitinib to its speciality portfolio: Analysts
Brokers remain positive about the acquisition and believe in the growth potential of Deuroxolitinib, which is a part of Concert's patent portfolio
BUSINESS
TV18 registers 12.8% rise in operational revenue at Rs 1,768 crore in Q3
The company said continued softness in macroeconomic environment led to soft advertisement demand which impeded growth and profitability
BUSINESS
How Zomato plans to achieve a balance in profitability and growth?
Zomato’s focus on growth may lead to delays in its short-run profitability targets but strategic initiatives hold the possibility of building a more sustainable business model with high-quality growth
BUSINESS
How do Nykaa's profitability goals look in light of increasing competition?
Although Nykaa is showing profitability, the business fundamentals look challenging as it faces competition in the BPC and fashion segments. A faster turnaround in the fashion segment and strategic initiatives may provide optimism to investors.
BUSINESS
Lupin trades higher on USFDA nod for generic bladder drug
Lupin Pharmaceutical got the United States' drug regulator's nod to market fesoterodine fumarate extended-release tablets
BUSINESS
Do telcos justify the optimism reflected in their stock prices?
The past few years have been difficult for India’s telecom companies. Their financials have been stressed because of low tariffs and fierce competition after Reliance Jio started services in September 2019 with its cheap data and call plans.
BUSINESS
Explainer: How telecom operators are gearing up for the launch of 5G services
The 5G auction witnessed optimistic bids and ended on a largely positive note, but a successful rollout may still face hiccups, compromising the early timeline targeted by the industry.
BUSINESS
MC Explainer | 5G spectrum auction: All you need to know about it
The bidding strategy of telcos for the C-band, the major 5G spectrum, remains a bit foggy because it is considered quite expensive.
